The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. The repeat offenders received their latest dressing-downs over a gathering of healthcare professionals and problems with the disclosure of transfers of value,

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot CagriSema caused economic damage after patients lost less weight using the drug than previously predicted.

NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.